← Database
M&A

QUOTIENT SCIENCES

Acquired by

PERMIRA

UNITED KINGDOM Life Sciences EV [500m GBP - 1b GBP] 07/2019

Target

QUOTIENT SCIENCES

Acquirer

PERMIRA

Context

Permira acquired a majority stake in Quotient Sciences from GHO Capital, which had owned the business since 2015. Under GHO's four-year ownership, the company underwent a major transformation, expanding its service offering into commercial manufacturing and establishing a significant presence in the United States through strategic investments and acquisitions. The transaction provided GHO with a strong exit while securing new capital for Quotient to continue its international expansion.

The transaction values QUOTIENT SCIENCES at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Quotient Sciences is a provider of outsourced drug development services. It is best known for its proprietary "Translational Pharmaceutics" platform, which integrates formulation development, real-time clinical manufacturing, and clinical pharmacology to accelerate the drug development process.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2019
LOGIN
LOGIN
LOGIN
2018
LOGIN
LOGIN
LOGIN

Other operations with QUOTIENT SCIENCES

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.